ABOUT HUGEL

New Hope, Better Life

History

GROWTH

  • 2015
    12
    Listed on KOSDAQ market
    Received IND approval for phase III clinical trial for
    botulinum toxin in the US
    09
    Increased stake in Across to 58.57%
    07
    Invested in AB Bio Inc.
    06
    Invested in Oilx Pharmaceuticals, Inc.
    Invested in Small Lab Co., Ltd.
    05
    Obtained EU CE mark for HA filler with lidocaine
    04
    Acquired Hugel Meditec, Inc.
    (medical device import and distribution company)
    01
    Launch of dermacosmetics brand ‘WELLAGE’
  • 2014
    04
    Obtained MFDS marketing approval for
    HA filler ‘The Chaeum volus 20’
  • 2013
    11
    Held the 1st H.E.L.F
    08
    Completed registration of Chuncheon no.2 manufacturing facility
    (cGMP / EU GMP standard)
    Acquired 47.62% stake in Across
  • 2012
    11
    Obtained additional indication approval for
    botulinum toxin(glabellar lines)
    04
    Registered Botulax® trademark to
    Korean Intellectual Property Office(KIPO)
    Received EU CE mark approval for HA filler ‘Dermalax’